The immune microenvironment as a guide for cancer therapies by Fridman, Wolf H.
The immune microenvironment as a guide
for cancer therapies
Wolf H. Fridman
Cordeliers Research Centre; INSERM UMRS872; Université Paris-Descartes; Université Pierre et Marie Curie; Paris, France
After a long period of disputed history
made of great hopes and subsequent
disillusions, the field of oncoimmunology
has now reached an unprecedented level
of recognition and respectability, both in
the scientific world and in the medical
universe. This results from the merge of
two streams of thought.
The first stream resulted from the
availability of recombinant strains of mice
lacking some or all components of the
immune system, sometimes crossed with
mice transgenic for oncogene expression,
yielding the demonstration that the lack
of immune components favors spontan-
eous tumor development. These experi-
ments have generated the 3E’s theory,
which describes the three phases of tumor
development, paraphrased as elimination,
equilibrium, and escape. At the initiation
of oncogenesis, most nascent tumor cells
would be eliminated by the immune
system. Only after genetic and phenotypic
editing, prospective cancer cells may form
a tumor that establishes an equilibrium
with the immune surveillance system.
Finally, tumor cells will undergo further
(epi)mutations and escape immune con-
trol. This theory implies that advanced
tumors become resistant to immune attack
and advanced cancer patients should
therefore not respond to immunotherapy.
The second stream, however, resulted
from the success of immunotherapeutic
approaches in advanced cancers including
metastatic disease. Thus, monoclonal anti-
bodies recognizing tumor cell associated
antigens were proven efficient in lym-
phoma (CD20), colorectal (EGF-R) and
breast (HER2-neu) cancer. Their bene-
ficial effect is mediated, at least partly,
through immune stimulation, for instance
by activating NK cells via the FccRIII
(CD16) receptors and by inducing a
memory T-cell response against the
targeted antigen. Monoclonal antibodies
raised against lymphocyte “checkpoint”
receptors (CTLA-4, PD1, CD137) or
their ligands (PDL-1) were reported to
increase patient survival in metastatic
melanoma, colorectal, pancreatic cancers
or lymphoma. That the anti-tumor effect
was indeed the consequence of unlocking
the immune system is supported by the
concomitant induction of autoimmune
reactions in patients treated with anti-
checkpoint antibodies and by the fact
that responding metastatic sites become
highly infiltrated by CD8
+ T cells. Thera-
peutic vaccination of patients with meta-
static, hormone refractory prostate cancer
resulted in significant increase in overall
survival accompanied by a specific immune
response to the immunizing prostatic
antigens. Finally, cellular therapies with
precursor or differentiated T cells, some-
times engineered to express a TCR that
recognizes a tumor-associated antigen,
can induce spectacular tumor regressions
and prolong overall survival. Beyond
these “classical” immunotherapies, a
recent revolutionary concept suggests that
chemotherapies are effective to induce
prolonged overall survival only if they
stimulate an anticancer immune response,
for instance by inducing immunogenic
tumor cell death that de facto converts
the cancer into a therapeutic vaccine.
Established in murine models, this con-
cept is supported in man by the fact that
polymorphisms of molecules involved
in immunogenic chemotherapies are asso-
ciated with patient survival. Also, some
anti-angiogenic therapies may modulate
the patient immune system by down-
regulating suppressor cells. Therefore, a
large body of murine models and clinical
trials is largely supportive of the fact that
the immune system is involved in tumor
control and that its manipulation may
result in increased survival, even in
patients with advanced cancer.
The effectiveness of immunotherapies
requires the stimulation of anticancer
immune responses. It has been established
for a long time that, except at the terminal
stage or in heavily pretreated patients,
cancer patients maintain a functional
immune system capable of protecting
them from infections. The last decade
has witnessed the analyses of large cohorts
of cancer patients, allowing to demon-
strate that the tumor’s immune micro-
environment influences clinical outcome.
Thus, a high density of memory T cells
with a Th1 cytokine pattern and cytotoxic
phenotype is a major positive prognostic
factor correlating with increased survival
of patients with colorectal, breast, urothe-
lial, lung, gastric, pancreatic, ovarian,
bladder, hepatocellular, cervical carcino-
mas, as well as with melanoma. This
observation has led to the proposal of
a new prognostic classification based on
the immune pattern of the tumor micro-
environment. This immune pattern is
predictive of survival at all stage of cancer
progression. For instance, in colorectal
cancer, 95% of the patients with local
disease (no lymph node or distant
metastases) exhibiting high infiltration
of CD8
+ and memory cells (CD45RO
+)
of the tumor were alive after 5y, as
compared with 27% with low densities
of these cells. Even at the disseminated
stage, patients with a high memory Tcell
infiltrate in their resected hepatic meta-
stases respond better to chemotherapy
and exhibit a better overall survival than
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www.landesbioscience.com OncoImmunology 261patients with a low T cell infiltrate in their
metastatic sites.
Altogether, these data support the
concept that an efficient immune reac-
tion may be shaped in the tumor micro-
environment, then circulate as memory
cells in the organism and finally delay
recurrence post therapy and cancer-
associated death. The question therefore
arises of which patients would benefit
from immunotherapeutic approaches.
This problem is far from being trivial
because, once resolved, it will result in
the selection of patients for immuno-
therapy, particularly in early stage cancers.
Treating an unselected cohort of early-
stage patients for which the expected
survival time is . 95% at 5y is unlikely
to yield statistically meaningful results
unless very large trials are envisaged.
In contrast, patients with a depressed
immune system and advanced, aggressive
cancer are unlikely to respond to any
kind of therapy including immunother-
apy. A definite proposal on which patients
should experience immuntherapy is there-
fore difficult to establish, and murine
models that reflect different interactions
between cancer and the immune system
should be designed and studied.
Before robust pre-clinical data guide
future immunotherapies, however, several
rules could be proposed for the further
evaluation and optimization of anticancer
immunotherapies. The first rule would be
to obligatorily characterize the immune
pattern of the tumor in all patients that
are renrolled in the trial, thus allowing to
establish retrospective classifications. The
second rule would be to launch prospec-
tive trials in which the immune pattern
is established for each patient. The third
rule would be to preferentially treat early-
stage patients with a low density of intra-
tumoral memory T and CD8 cells with
the aim of obtaining a clinical response
within a short timeframe. Conversely, at
the metastatic stage, only patients with
signs of an efficient anticancer immune
response should be included in innovative
clinical trials.
We can anticipate that appropriate
mouse models as well as intelligently
designed clinical trial will fine tune
optimal antineoplastic therapies as they
demonstrate an ever more important role
of the anticancer immune response.
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